| Overview |
| bsm-51241M |
| SUMO2 (7A3) Monoclonal Antibody |
| WB, IF(ICC), IF |
| Human, Rat |
| Specifications |
| Unconjugated |
| Mouse |
| Purified His-tagged SUMO2 protein was used to produced this monoclonal antibody. |
| Monoclonal |
| 7A3 |
| IgG2b |
| 0.5ug/ul |
| Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C for 12 months. |
| Target |
| 6613 |
| P61956 |
| HSMT3; SMT3B; SUMO3; Smt3A; SMT3H2; Small ubiquitin-related modifier 2; SUMO-2; SMT3 homolog 2; SUMO-3; Sentrin-2; Ubiquitin-like protein SMT3B; SUMO2 |
| Ubiquitin-like protein that can be covalently attached to proteins as a monomer or as a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2, CBX4 or ZNF451 (PubMed:26524494). This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Polymeric SUMO2 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins (PubMed:18408734, PubMed:18538659, PubMed:21965678, PubMed:9556629). Plays a role in the regulation of sumoylation status of SETX (PubMed:24105744). |
| Application Dilution |
| WB |
1:300-5000 |
| IF(ICC) |
1:50-200 |
| IF |
|
Powered by Bioz